Our team

Company Overview

BioDrop Solutions SIA is a diagnostics company based in Riga, Latvia, developing innovative tear-based diagnostics. Our smart contact lens platform collects microRNA from tear fluid, enabling early detection and monitoring of brain cancers like glioma — with unmatched comfort and speed.

The company is supported by the Investment and Development Agency of Latvia (LIAA) and benefits from Latvia’s innovation-friendly environment, strategic EU location, and R&D incentives.

With scientific operations in Europe and executive leadership in the U.S., BioDrop bridges cutting-edge biotech and global commercialization.

Baruh Polis MD, PhD, MBA

Founder & Chief Scientific Officer

Baruh Polis is a neuroscientist and clinical researcher with deep expertise in brain science and translational medicine. He has led numerous academic and applied research projects across Europe, with a strong focus on neurodegenerative diseases and non-invasive diagnostics. At BioDrop, Baruh leads all scientific and R&D efforts, bridging academic innovation with real-world clinical needs.

Now Seeking: Angel Investor & Board President

We are currently seeking a strategic angel investor to join BioDrop at this pivotal early-growth stage.

In exchange for capital investment, we are offering:

• Ownership equity aligned with long-term company growth

• Optional Board President role with consultative influence

• Direct involvement in a transformative non-invasive diagnostic technology

This partnership will support early product development, strengthen investor visibility, and help scale BioDrop into a category-defining diagnostics company.

Benjamin Medvin, MSc

Chief Executive Officer (CEO)

Benjamin Medvin is a biotechnology executive with over a decade of international experience in commercialization, capital formation, and strategic partnerships. He has led fundraising efforts across North America, LATAM, and MENA, worked with national health ministries, and represented leading CRDMOs in cell and gene therapy, synthetic biology, and nanocarriers. At BioDrop, Benjamin oversees go-to-market strategy, investor engagement, and the commercialization of tear-based diagnostics.